WASHINGTON, Oct. 3, 2018 /PRNewswire/ — The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations, announced today that 16 of its member companies will present data from their clinical and research programs at IDWeek 2018 to be held October 3-7 in San Francisco. AWG members are presenting a total of 40 poster presentations, four oral abstract presentations and four features within the symposium entitled “Exploring the Antibiotic Pipeline 2018.”
IDWeek is an annual scientific meeting that brings together infectious disease professionals to present and discuss the latest approaches in prevention, diagnosis, treatment, and epidemiology of infectious diseases.
“We are pleased to have a record number of AWG member companies presenting at IDWeek this year,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara Therapeutics and Chairman of the AWG. “AWG members look forward to presenting data on new antimicrobial molecules in development, including findings that explore the role of novel therapies against antibiotic-resistant organisms, as well as topics in rapid diagnostics. IDWeek provides a rich opportunity to engage with infectious disease professionals from various backgrounds about novel agents, clinical trials, PK/PD studies and a host of different infections with the common goal of improvement of patient care and public health.”
The following AWG member companies will be presenting at IDWeek 2018: Amplyx Pharmaceuticals, Arsanis Inc. (NASDAQ: ASNS), Cidara Therapeutics, Inc. (NASDAQ: CDTX), ContraFect Corporation (NASDAQ: CFRX), Entasis Therapeutics, Iterum Therapeutics plc (NASDAQ: ITRM), Melinta Therapeutics, Inc. (NASDAQ: MLNT), Motif Bio plc (AIM/NASDAQ: MTFB), Nabriva Therapeutics Plc (NASDAQ: NBRV), Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), SCYNEXIS, Inc. (NASDAQ: SCYX), Spero Therapeutics, Inc. (NASDAQ: SPRO), Summit Therapeutics plc (AIM:SUMM,NASDAQ: SMMT), T2 Biosystems, Inc. (NASDAQ: TTOO), Theravance Biopharma, Inc. (NASDAQ: TBPH) and Viamet.
For more information on AWG member company presentations and access to specific abstracts, please visit: https://www.antimicrobialsworkinggroup.org/idweek-2018/.
About The Antimicrobials Working Group
AWG was founded in 2012 with the vision of utilizing collective power to improve the regulatory, investment, and commercial environment for emerging infectious disease companies. Today, AWG is comprised of nineteen antimicrobials and diagnostics companies: Amplyx Pharmaceuticals, Aridis Pharmaceuticals, Arsanis Inc., Cidara Therapeutics Inc., ContraFect Corporation, Entasis Therapeutics Inc., Iterum Therapeutics Ltd., Melinta Therapeutics Inc., Motif Bio PLC, Nabriva Therapeutics US Inc., Paratek Pharmaceuticals Inc., SCYNEXIS Inc., Spero Therapeutics, Inc., Summit Therapeutics plc, T2 Biosystems Inc., Theravance Biopharma U.S. Inc., Viamet, Vical Incorporated, and Zavante Therapeutics Inc.
For more information, visit: www.antimicrobialsworkinggroup.org
About The Conafay Group
The Conafay Group, led by Stephen R. Conafay, Principal, is a life-sciences government relations firm based in Washington D.C. that serves as Washington counsel and coalition manager for AWG.
For more information, visit: www.conafaygroup.com
SOURCE Antimicrobials Working Group (AWG)